Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab [4]

Clinical and Experimental Ophthalmology

Volumn 36, Issue 1, 2008, Pages 94-96

  Peter, Silvia ^a   Hausmann, Norbert ^a   Schuster, Antonius ^b   Boehm, Hubert Friedrich ^a  

^a ACADEMIC TEACHING HOSPITAL FELDKIRCH   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEFTRIAXONE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AGED; BODY TEMPERATURE; CASE REPORT; COLON CANCER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INFECTION; LETTER; LEUKOCYTE COUNT; LEUKOENCEPHALOPATHY; LEUKOPENIA; METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; PUPIL REFLEX; SEIZURE; VISUAL ACUITY; VISUAL IMPAIRMENT; WHITE MATTER;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLONIC NEOPLASMS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME;

EID: 39649097820     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2007.01658.x     Document Type: Letter

References (5)

1. Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: A misnomer reviewed. Intern Med J 2005; 35: 83-90.
2. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354: 980-1.
3. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354: 981-2.
4. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006; 63: 1475-8.
5. Weis SM. Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005; 437: 497-504.